Comparison of Efficacy and Safety of Two Different Types of Botulinum Toxin Type A in Moderate to Severe Cervical Dystonia

Browse trials for

• Torticollis 139

Torticollis

139 studies on the registry are indexed under Torticollis; 21 are open to participants now.

This study's enrollment of 145 is above the median of 42 across 93 interventional studies indexed under Torticollis.

Lead sponsor

Allergan is the lead sponsor of 499 studies on the registry; none are open to participants now.

Of its 91 completed or terminated interventional studies of FDA-regulated products, 89 (98%) have results posted.

Study arms

• Active comparator
  BOTOX®

  botulinum toxin type A (BOTOX®)

  Biological: botulinum toxin type A

• Active comparator
  Dysport®

  botulinum toxin type A (Dysport®)

  Biological: botulinum toxin type A

Interventions

• Biologicalbotulinum toxin type A

  200 Units at Visit 1 (Day 1)

  Also known as: BOTOX®

• Biologicalbotulinum toxin type A

  750 Units at Visit 1 (Day 1)

  Also known as: Dysport®

Primary outcomes

1. Dysphagia Incidence Over 10 Weeks

   Dysphagia Incidence (difficulty swallowing) was defined as the number of patients reporting at least 1 treatment-emergent dysphagia event at any point in the study. Occurrences of dysphagia were captured as spontaneous events or were assessed during study visits using the Structured Symptom Interview (SSI) and the Dystonia Study Group Dysphagia Interview (DSGDI) for symptoms of difficulty swallowing; coughing while eating and drinking; choking while eating or drinking; or difficulty swallowing solids or liquids.

   Time frame: 10 weeks

Secondary outcomes

1. Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Total Score at Week 4

   The TWSTRS assessments were conducted at each study visit. The TWSTRS is an assessment scale used to measure the impact of cervical dystonia on patients. It is comprised of 3 subscales: Severity, Disability, and Pain, each of which is scored independently. The total of these 3 comprises the TWSTRS total score which is scored from 0 (least symptoms) to 85 (worst symptoms). Higher scores indicate a greater degree of symptom severity.

   Time frame: Baseline, Week 4

2. Physician Assessment of Cervical Dystonia Severity at Week 4

   Physician assessment of cervical dystonia severity. The rating was assessed on a scale of 0 to 10, with higher scores denoting greater severity: 0 represented 'No evidence of dystonia' and 10 represented 'Worst cervical dystonia ever.'

   Time frame: Baseline, Week 4

3. Global Assessment of Benefit by Physician at Week 4

   Physician evaluation of benefit from botulinum toxin type A treatment for cervical dystonia. Ratings were on a scale of +4 to -4, with higher scores denoting improvement in cervical dystonia: +4 was 'Complete abolishment of signs and symptoms (about 100% improvement)', 0 represented 'Unchanged', and -4 represented 'Very marked worsening (about 100% worse or greater).'

   Time frame: Week 4

4. Global Assessment of Benefit by Patient at Week 4

   Patient evaluation of benefit from botulinum toxin type A treatment for cervical dystonia. Ratings were on a scale of +4 to -4, with higher scores denoting improvement in cervical dystonia: +4 was 'Complete abolishment of signs and symptoms (about 100% improvement)', 0 represented 'Unchanged', and -4 represented 'Very marked worsening (about 100% worse or greater).'

   Time frame: Week 4

5. Patient Assessment of Need for Retreatment at Week 4

   Patients were queried regarding their need for another injection of botulinum toxin type A for cervical dystonia. Patients were required to answer "How would you rate your need for another injection of botulinum toxin type A for cervical dystonia using the following scale?". The response options included 'absolutely requires injection', 'very much requires injection', 'somewhat requires injection' and 'does not require injection'.

   Time frame: Baseline, Week 4

6. Patient Visual Analog Assessment of Pain at Week 4

   Patients were required to assess their pain using a Visual Analog Scale in reference to their current perception of pain at that visit. This scale consisted of a line measuring 100 mm, and patients were instructed to put a mark on the line at the point that best described 'How much pain you are having right now'. Higher scores denoted higher pain intensity: 0 indicated 'No pain' and 100 indicated 'Worst possible pain'.

   Time frame: Baseline, Week 4

7. Physician Comparison of Benefit to Previous Injections at Week 10

   Physicians assessed the improvement in cervical dystonia after the study treatment compared to previous treatment(s) for each patient. Physicians were required to answer "How would you rate the benefit of the current treatment of cervical dystonia with botulinum toxin type A compared to the previous treatment using the following scale?". The response options were 'much worse', 'worse', 'somewhat worse', 'same as previous', 'somewhat better', 'better', and 'much better'.

   Time frame: Week 10

8. Patient Comparison of Benefit to Previous Injections at Week 10

   Patients assessed the improvement in cervical dystonia after receiving the study treatment compared to previous treatment(s). Patients were required to answer "How would you rate the benefit of the current treatment of cervical dystonia with botulinum toxin type A compared to the previous treatment using the following scale?". The response options were 'much worse', 'worse', 'somewhat worse', 'same as previous', 'somewhat better', 'better', and 'much better'.

   Time frame: Week 10

Baseline characteristics